Trials / Unknown
UnknownNCT02474667
Reduce the Severity of DGF in Recipients of a Deceased Donor Kidney
A Multicenter, Prospective, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study of ANG-3777 (Formerly BB3) to Improve Graft Function and Reduce the Severity of Kidney Dysfunction or Delayed Graft Function Following Kidney Transplantation in Recipients of a Deceased Donor Kidney
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 253 (actual)
- Sponsor
- Angion Biomedica Corp · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The major objective is to demonstrate the safety and efficacy of ANG-3777 in improving graft function and reducing the severity of delayed graft function (DGF) in recipients at high risk of DGF after receiving a deceased donor renal allograft.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ANG-3777 | |
| OTHER | Placebo |
Timeline
- Start date
- 2016-03-01
- Primary completion
- 2021-09-01
- Completion
- 2021-09-01
- First posted
- 2015-06-18
- Last updated
- 2021-06-03
Locations
30 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02474667. Inclusion in this directory is not an endorsement.